| Application no. and date | 20828324.2 (espacenet) (Federated) (European Patent Register), 20201215 | | Patent/reg. no. and date | DK/EP 4076465, 20231115 | | Publication date | 20221026 | | Priority no. and date | US 201962949688 P, 20191218, US 202063066755 P, 20200817, US 202063108745 P, 20201102 | | EP pub. no. and date |
EP 4076465 20221026 | | Effective date | | | Applicant/owner | Pfizer Inc., 66 Hudson Boulevard East
New York, NY 10001-2192, US | | Applicant ref. no. | | | Inventor | LI, Meng, c/o Pfizer Inc. 10777 Science Center Drive
San Diego, California 92121, US,
LIAO, Kai-Hsin, c/o Pfizer Inc. 10777 Science Center Drive
San Diego, California 92121, US,
YAMAZAKI, Shinji, 3884 Quarter Mile Drive
San Diego, California 92130, US | | Representative | | | Opponent | | | IPC Class | A61K 31/337 (2006.01) , A61K 31/519 (2006.01) , A61K 39/00 (2006.01) , A61K 9/00 (2006.01) , A61K 9/20 (2006.01) , A61P 35/00 (2006.01) | | Title | ONCE DAILY CANCER TREATMENT REGIMEN WITH A PRMT5 INHIBITOR | | Int. application no. | IB2020061957 | | Int. publication no. | WO2021124096 | | Related patent (certificate) | | | Status | Enhedspatent registreret | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
